TUB.BR TUBIZE-FIN | BE0003823409
Company Profile
Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous system. The company was founded in 1928 and is based in Brussels, Belgium.
Latest News
Cloudbeds rolls out data intelligence tool for hotel groups
Hotel Management Network • 07/27/2026
KOC agrees $16bn pipeline deal with Blackstone, Brookfield, KKR
Offshore Technology • 07/27/2026
Meliá fully withdraws from Cuba amid economic crisis – report
Hotel Management Network • 07/27/2026
Man Group PLC : Form 8.3 - AMG Critical Materials N.V
GlobeNewswire • 07/27/2026
| Sector | Healthcare |
| Industry | Biotechnology |
| Website | https://www.financiere-tubize.be |
| Audit Risk | 10 |
| Board Risk | 9 |
| Overall Risk | 8 |
| Market Cap | 9.32B |
| Trailing P/E | 99.71 |
| Dividend Rate | 1.08 |
| Dividend Yield | 0.51% |
| Trailing Annual Div. Rate | 1.08 |
| Trailing Annual Div. Yield | 0.51% |
| Trailing EPS | 2.1 |
| Book Value | 42.36 |
| Price-to-Book | 4.94 |
| Enterprise-to-EBITDA | -3,146.35 |
| Ex-Dividend Date | 05/07/2026 |
| Earnings Date | |
| Earnings Call Date |